Guerbet Logo

Guerbet

Offers medical imaging solutions, from contrast agents to AI, for healthcare professionals.

GBT | PA

Overview

Corporate Details

ISIN(s):
FR0000032526 (+3 more)
LEI:
969500WV1U1WQ059L135
Country:
France
Address:
15 RUE DES VANESSES, 93420 VILLEPINTE
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Guerbet is a global leader in medical imaging, specializing in diagnostic and interventional imaging solutions for healthcare professionals. Since its establishment in 1926, the company has developed and commercialized a comprehensive portfolio that includes contrast agents, medical devices, delivery systems, and digital and AI-powered solutions. Guerbet's products are utilized to improve the diagnosis and treatment of major disease areas such as cancer, as well as cardiovascular, inflammatory, and neurodegenerative diseases. The company focuses on providing innovative and safe solutions to enhance patient care and support radiology professionals worldwide.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-12-02 17:45
Business and Financial Review
GUERBET : Ajustement des objectifs financiers 2025.
French 157.0 KB
2025-12-02 17:45
Earnings Release
GUERBET : Adjustment of 2025 financial targets.
English 150.5 KB
2025-11-24 17:44
Declaration of Voting Results & Voting Rights Announcements
GUERBET : Nombre d'actions et de droits de vote composant le capital de la soci…
French 153.1 KB
2025-11-19 13:47
Report Publication Announcement
GUERBET : Calendrier financier de l’exercice 2026
French 198.7 KB
2025-11-19 13:47
Report Publication Announcement
GUERBET : Financial agenda for 2026
English 172.2 KB
2025-10-23 17:45
Earnings Release
Guerbet : Chiffre d’affaires au 30 septembre 2025. Retour de la croissance au 3…
French 294.9 KB
2025-10-23 17:45
Earnings Release
Guerbet : Revenue at September 30, 2025. Return to growth in Q3 2025. Confirmat…
English 305.6 KB
2025-10-14 17:30
Declaration of Voting Results & Voting Rights Announcements
GUERBET : Nombre d'actions et de droits de vote composant le capital de la soci…
French 158.6 KB
2025-09-24 17:45
Earnings Release
Guerbet : H1 2025 results : H1 revenue: €387.8 million, down 5.4% at CER and on…
English 524.6 KB
2025-09-24 17:45
Earnings Release
Guerbet : Résultats semestriels 2025 : Chiffre d’affaires du 1er semestre : 387…
French 496.3 KB
2025-09-22 17:45
Board/Management Information
Guerbet : Evolution de la Direction Générale
French 134.4 KB
2025-09-22 17:45
Board/Management Information
Guerbet : Change in General Management
English 113.8 KB
2025-09-18 17:45
Declaration of Voting Results & Voting Rights Announcements
GUERBET : Nombre d'actions et de droits de vote composant le capital de la soci…
French 159.1 KB
2025-09-15 17:50
Earnings Release
Guerbet : Ajustement des objectifs financiers annuels 2025
French 209.3 KB
2025-09-15 17:50
Earnings Release
Guerbet : Adjustment of 2025 full-year financial targets
English 186.1 KB

Automate Your Workflow. Get a real-time feed of all Guerbet filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Guerbet

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Guerbet via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2024-08-19 N/A Other Buy 142 4,989.31 EUR
2024-08-15 N/A Other Buy 195 6,678.75 EUR
2024-08-12 N/A Other Buy 1,000 34,350.00 EUR
2024-04-18 N/A Other Sell 550 17,699.00 EUR
2023-11-30 N/A Other Sell 700 12,684.00 EUR
2023-11-03 N/A Other Buy 1 17.92 EUR
2023-10-30 N/A Other Buy 1,000 17,000.00 EUR
2023-10-25 N/A Other Buy 1,000 16,800.00 EUR
2023-10-24 N/A Other Buy 1,000 16,460.90 EUR
2023-05-04 N/A Other Buy 300 4,938.00 EUR

Peer Companies

A global CDEMO offering end-to-end solutions for antibody therapeutics and biologics.
South Korea
334970
Develops affordable biosimilars and novel antibody drugs for life-threatening diseases.
Singapore
950210
Prestige Consumer Healthcare Inc. Logo
Develops and markets leading over-the-counter brands for personal healthcare and wellness.
United States of America
PBH
Prime Medicine, Inc. Logo
Developing 'search and replace' gene editing therapies to treat genetic disorders.
United States of America
PRME
Probi Logo
Develops and manufactures clinically proven probiotics for B2B supplement & nutrition partners.
Sweden
PROB
Develops scientifically validated probiotics for cardiometabolic health for consumers & partners.
United Kingdom
PBX
Processa Pharmaceuticals, Inc. Logo
Develops next-gen chemo and therapies for chronic and life-threatening diseases.
United States of America
PCSA
Develops protein-based immunotherapies for metabolic diseases, immune disorders, and cancer.
South Korea
296160
PROKIDNEY CORP. Logo
Develops cellular therapies to preserve kidney function for patients with advanced Chronic Kidney Disease.
United States of America
PROK
ProPhase Labs, Inc. Logo
Genomics, diagnostics, contract manufacturing, and OTC health & wellness solutions provider.
United States of America
PRPH

Talk to a Data Expert

Have a question? We'll get back to you promptly.